Abstract
Background: Elzovantinib is a novel, type I tyrosine kinase inhibitor (TKI) that targets MET, SRC, and CSF1R. Genetic alterations in MET, including exon 14 skipping (Δex14) mutations and other oncogenic mutations, amplifications, and fusions are present in many tumor types. The Phase 1 SHIELD-1 trial (NCT03993873) is evaluating safety, pharmacokinetics (PK), and preliminary activity of elzovantinib in patients (pts) with advanced solid tumors harboring genetic MET alterations. An early analysis included 46 efficacy evaluable pts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
